An editorial notes that this phase II study provides promising results of a novel agent for gout that appears to tackle at least 2 key aspects of gout management in a single drug; namely lowering serum urate and providing flare prophylaxis with the potential for a new drug class that could be coined “ULAFT” (urate lowering antiflare therapy). However, results from well conducted phase III trials are needed to see how this drug will fit into the relatively small existing gout care armamentarium.